We also evaluated T22‐GFP‐H6‐FdU capacity to prevent metastasis as compared to free oligo‐FdU, by registering the percent of mice with undetectable metastases at the end of treatment (Mets‐free mice) and the reduction in number and size of Mets foci in mice with detectable metastases (Mets+ mice) at the end of the experiment, using the CXCR4+ SW1417 orthotopic bioluminescent CRC model, which metastasizes to lymph nodes (LN), liver (LV), lung (LG), and peritoneum (PTN), starting treatment 1 week after CRC implantation and following a schedule of 20 μg, q3d, 12 doses (Appendix Fig S5B). The gene discussed is CXCR4; the disease is colorectal carcinoma.